+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 65Years
All Genders
ID07082192

Evaluating the Effects and Safety of CB03-154 in Adults With Amyotrophic Lateral Sclerosis Using Different Daily Oral Doses Compared to Placebo in a Randomized, Double-Blind Study with Open-Label Extension

Led by Shanghai Zhimeng Biopharma, Inc. · Updated on 2026-09-22

240

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug CB03-154 for the treatment of Amyotrophic Lateral Sclerosis ALS in adults aged 18 to 65 years. The study aims to determine whether CB03-154 can delay disease progression, improve function, and extend survival compared to a placebo. Safety and medical problems related to CB03-154 use will also be assessed in this multicenter, randomized, double-blind, placebo-controlled Phase IIIII study with an open-label extension. Participants will be randomly assigned to one of four groups to receive daily oral doses of CB03-154 at 5mg, 10mg, or 15mg, or a matching placebo for 39 weeks during the double-blind phase. Those entering the open-label extension may continue treatment for an additional 39 weeks. Study visits occur approximately every 2 to 3 months with interim telephone follow-ups. Participants will keep diaries to record daily medication intake and reasons for any unplanned medications. Throughout the study, participants will undergo regular clinic visits for assessments including the ALS Functional Rating Scale-Revised ALSFRS-R, survival tracking, respiratory function tests, depression scales, quality of life questionnaires, and blood tests for biomarkers such as Neurofilament Light Chain. Safety monitoring includes observation of adverse effects and medication adherence. The total participation may last up to 78 weeks if including the open-label extension, with data collected to evaluate both efficacy and safety.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Research Team

D

Dongsheng Fan, MD,PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here